Trisomy Disorders

Abnormal growth in noonan syndrome: the challenge of optimal therapy.

Posted on: September 25, 2009

Abnormal growth in noonan syndrome: the challenge of optimal therapy. 

Savage MO, Padidela R, Kirk JM, Malaquias AC, Jorge AA.

Department of Endocrinology, Barts and the London School of Medicine and Dentistry, London, UK.

Noonan syndrome (NS) is a phenotypically heterogeneous condition frequently associated with short stature. Genetic investigations have identified mutations in several genes, e.g.PTPN11, KRAS, RAF and SOS1 in patients with the NS phenotype and related disorders such as LEOPARD, Costello and Cardiofacio- cutaneous syndromes. In NS, PTPN11 mutations are present in 29-60% of cases. The degree of short stature does not associate closely with the presence of a mutation; however, some PTPN11-positive patients have decreased growth hormone (GH)-dependent growth factors consistent with mild GH insensitivity. GH therapy induces short-term increases in height velocity over 1-3 years, and is likely to improve adult height.

PMID: 19550387 [PubMed – indexed for MEDLINE]

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

September 2009
« Jan   Feb »

Blog Stats

  • 79,223 hits

Top Posts

%d bloggers like this: